EVgenii S.
- Country
- Germany
- Department
- Hematology-Oncology-Medical Clinic A
Research Overview
- A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)
- Phase II Study of Glofitamab-Based Induction Followed by CAR‑T Cell Therapy in High‑Risk Relapsed/Refractory Large B‑Cell Lymphoma
- Randomized Phase II Study of Teclistamab + Daratumumab‑Lenalidomide‑Dexamethasone (Tec‑DRd) vs Daratumumab‑Lenalidomide‑Dexamethasone (DVRd) in Transplant‑Eligible NDMM
Data & Insights
Has run more than one trial at 114 of 239 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in innovative therapeutic approaches for multiple myeloma, with particular focus on newly diagnosed multiple myeloma treatment strategies.
- Novel Combination Therapies
- Induction Treatment Optimization
- Maintenance Therapy Strategies
Their research encompasses various administration routes and therapeutic combinations for optimal patient outcomes.
Lymphoma Studies
The investigator conducts research in various lymphoma subtypes, particularly focusing on diffuse large B-cell lymphoma and marginal zone lymphoma.
- B-Cell Lymphoma Therapeutics
- Novel Antibody Treatments
- Treatment Response Assessment
Their work includes evaluation of targeted therapies and immunotherapeutic approaches in lymphoid malignancies.
Therapeutic Innovation
The investigator explores minimal residual disease assessment and response evaluation using advanced methodologies.
- Treatment Response Monitoring
- Immunotherapy Applications
- Clinical Outcome Assessment
Their research incorporates modern diagnostic techniques and response criteria for hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.